Zipalertinib

3 trials 2 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

1 Completed trials

1 Sponsors

10 Countries

Phase III

Phase II

Phase III: 2 Phase II: 1

Oversight events:

1 serious breach 7 temporary halts across 2 trials

View oversight register →

Indications tested

Non-small cell lung cancer 3

Sponsors using this IMP

Taiho Oncology Inc. 3

All trials

3 total

Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Phase III 9 countries Taiho Oncology Inc.
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced… Recruiting

2023-503865-48-00 Phase II 4 countries Taiho Oncology Inc.
A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma… Ended

2023-503575-21-00 Phase III 10 countries Taiho Oncology Inc.

Showing 1–3 of 3 trials

← All drugs A–Z